What does licensing and royalty revenue — total revenue mean?

This metric represents the total gross revenue generated from licensing intellectual property and royalty payments derived from commercialized products developed through the company's technology platform. It serves as a key indicator of the successful monetization of the company's research and development efforts and the commercial adoption of its partnered assets. Growth in this area reflects the company's ability to transition from early-stage discovery services to long-term, recurring revenue streams.

AbCellera Biologics Inc. (ABCL) Licensing and royalty revenue — Total Revenue

Screener

Other product segments

Research fees

$3.9M-41.2%

Similar metrics at other companies

MRNALicensing and royalty revenue — Total Revenue

$0-100%

MRAMLicensing, royalty, engineering services and other revenue — Total Revenue

$3.42M+62.2%

SHAKLicensing revenue — Total Revenue

$14.18M+7.1%

DLBLicensing — Total Revenue

$372.25M+7.6%

MRAMLicensing — Total Revenue

$0-100%

GHLicensing and other — Total Revenue

$2.14M+15.3%

Other financials

Income statement

See full

Revenue$4.1M-76.3%

Operating income-$62.8M-26.6%

Net income-$55.4M-59.6%

EPS (diluted)-$0.18-50.0%

Balance sheet

See full

Cash & equivalents$145.1M+23.5%

Total debt$135.6M-4.5%

Total equity$896.0M-11.0%

Total assets$1.3B-6.7%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$2.1M-84.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.99B+62.2%

Enterprise value$1.98B+58.2%

P/S30.1×-7.3×

Profitability

See full

Operating margin-340.3%-127pp

Net margin-248.8%-83.6pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-17.3%+2.1pp

Debt / equity0.2×0.0×

Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 4:28 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001703057-26-000046

Line item	Three months ended June 30, 2025	Three months ended June 30, 2026	Six months ended June 30, 2025	Six months ended June 30, 2026
Revenue:
Research fees	$6,639	$3,901	$10,707	$12,021
Licensing and royalty revenue	10,445	149	10,613	341
Total revenue	17,084	4,050	21,320	12,362
Operating expenses:
Research and development(1)	39,213	45,987	81,711	92,649
Sales, general, and administrative(1)	21,986	13,850	41,054	26,185
Depreciation and amortization	5,470	6,990	10,801	13,828

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s licensing and royalty revenue — total revenue?: AbCellera Biologics Inc. (ABCL) reported licensing and royalty revenue — total revenue of $149K in Q2 2026.
What does licensing and royalty revenue — total revenue mean?: This metric represents the total gross revenue generated from licensing intellectual property and royalty payments derived from commercialized products developed through the company's technology platform. It serves as a key indicator of the successful monetization of the company's research and development efforts and the commercial adoption of its partnered assets. Growth in this area reflects the company's ability to transition from early-stage discovery services to long-term, recurring revenue streams.